register

News - Pharmaceuticals

NSW government invests $40 million in Chinese pharma deal

Health Industry Hub | December 8, 2021 |

Pharma News: Eight new pharmaceutical clinical trials with a value of more than $40 million are planned after NSW Government supported a joint venture between Sydney-based company George Clinical and Guangzhou (China) based pharmaceutical company Link Health at the 28th biennial NSW-Guangdong Joint Economic Meeting (JEM).

Stuart Ayres, Minister for Jobs, Investment, Tourism and Western Sydney, said George Clinical has deep experience in leveraging its scientific networks, clinical protocol design, study management, data science and global trial execution.

“Bringing together the complementary strengths of both companies will allow China and Australia to capitalise on the tremendous growth in the pharmaceutical industry in areas such as trial execution, marketing authorisation and commercialisation,” Mr Ayres said.

“The joint venture of Link Health and George Clinical (Link-George) will optimise the tremendous growth in pharma licensing and drug development and I congratulate them on cementing this significant new partnership.”

“We are very excited to enter into this joint venture with Link Health as part of a novel platform providing a one-stop service for in-licensing, clinical development, marketing authorization and commercialisation.  This will enable both companies to further optimise the tremendous growth in the pharmaceutical industry in China and, in so doing, help to advance clinical research in this region,” stated George Clinical Chief Executive Officer, James Cheong.  

Link Health brings in-depth knowledge in the evaluation of pharmaceutical targets, consultation on pharmaceutical licensing and the regulatory and commercial landscape in China.

Dr. Song Yan, CEO and founder of Link Health, said “Through this joint venture, Link Health and George Clinical will complement each other’s advantages in the fields of drug-ability evaluation, medical writing, medical statistics, clinical protocol design and real-world research, and jointly provide Link Health and its customers with end-to-end integrated solutions.”

Commercial Director and Country Head of George Clinical Dr Jacqueline Thorn shared the excitement of the joint venture.

“Both parties acknowledge the help and support of the NSW and Guangdong governments, including the JEM itself, in achieving this great outcome,” Dr Thorn said.


News - MedTech & Diagnostics

Roche unlocks new horizons for genomic research in Asia Pacific

Roche unlocks new horizons for genomic research in Asia Pacific

Health Industry Hub | November 9, 2026 |

Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]

More


News - Pharmaceuticals

'Unexpected and Surprising': Novartis’ Lp(a) setback raises tough questions for Amgen and Lilly - Professor Stephen Nicholls, Victorian Heart Hospital

‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly

Health Industry Hub | November 9, 2026 |

The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]

More


News - MedTech & Diagnostics

More public hospitals turn to same-day hip and knee surgery but recovery risks persist

More public hospitals turn to same-day hip and knee surgery, but key blind spots persist

Health Industry Hub | November 9, 2026 |

Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]

More


News - Pharmaceuticals

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning

Health Industry Hub | November 9, 2026 |

The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]

More


This content is copyright protected. Please subscribe to gain access.